Physician profile
Ray D Page
NPI 1669422143
$45,069.50
in general payments reported to CMS, 2019-2025
93 companies · $3,275 in 2025
The $3,275 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $8,170 · 2020: $4,303 · 2021: $7,473 · 2022: $1,683 · 2023: $17K · 2024: $2,928 · 2025: $3,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $11K · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,433.00 |
| Food and Beverage | $10,695.41 |
| Education | $312.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $5,340.53 | 2019-2025 | Enhertu, Datroway |
| Verastem, INC. | $5,184.93 | 2019-2020 | |
| Astellas Pharma US INC | $4,115.43 | 2019-2024 | Xospata, Vyloy, Padcev |
| Abbvie INC. | $3,807.39 | 2019-2025 | |
| Puma Biotechnology, INC. | $3,205.02 | 2019-2025 | Nerlynx |
| Janssen Biotech, INC. | $2,978.05 | 2019-2025 | Erleada, Talvey, Tecvayli |
| Jazz Pharmaceuticals INC. | $2,435.10 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,240.00 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| G1 Therapeutics, INC. | $1,514.88 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $1,208.00 | 2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $881.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $762.71 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Genentech USA, INC. | $686.92 | 2019-2025 | Tecentriq Hybreza, Tecentriq, Alecensa |
| Pfizer INC. | $676.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $674.38 | 2019-2025 | Lynparza, Imfinzi, Tagrisso |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $618.03 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $441.35 | 2019-2025 | Jakafi, Monjuvi, Monjuvi |
| Lilly USA, LLC | $428.08 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $394.50 | 2019-2025 | Trodelvy |
| Amgen INC. | $382.30 | 2019-2023 | Nplate, Kyprolis, Xgeva |
| Bayer Healthcare Pharmaceuticals INC. | $374.65 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $303.53 | 2019-2025 | Onivyde, Somatuline Depot |
| Genzyme Corporation | $293.54 | 2019-2025 | |
| Kite Pharma, INC. | $291.80 | 2022-2025 | Yescarta |
| Pharmacosmos Therapeutics INC. | $290.76 | 2022-2025 | Monoferric |
| Exelixis INC. | $289.13 | 2019-2025 | Cabometyx |
| Celgene Corporation | $282.53 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Immunocore Limited | $270.54 | 2023-2025 | Kimmtrak |
| Glaxosmithkline, LLC. | $266.39 | 2019-2025 | Ojjaara, Jemperli |
| Regeneron Healthcare Solutions, INC. | $247.03 | 2019-2025 | Libtayo |
| Seagen INC. | $196.54 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Sirtex Medical INC | $191.24 | 2019-2025 | Sir-Spheres Microspheres |
| Eisai INC. | $187.99 | 2019-2025 | |
| Stemline Therapeutics INC. | $179.10 | 2023-2025 | Orserdu |
| Genmab U.S., INC. | $175.61 | 2023-2024 | Epkinly, Tivdak |
| Blueprint Medicines Corporation | $166.47 | 2023-2025 | Ayvakit |
| Novocure INC. | $160.14 | 2020-2025 | Optune Lua (Novottf-200t) |
| Spectrum Pharmaceuticals INC. | $152.19 | 2023-2024 | Rolvedon |
| Tempus Ai, INC | $149.26 | 2024 | |
| Emd Serono, INC. | $147.91 | 2019-2025 | Bavencio |
| Caris Mpi, INC. | $145.46 | 2025 | Mi Cancer Seek |
| Sobi, INC | $137.41 | 2023-2025 | |
| Pharmaessentia USA Corporation | $130.95 | 2023-2025 | Besremi |
| Teva Pharmaceuticals USA, INC. | $125.91 | 2019 | |
| Intuitive Surgical, INC. | $125.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.71 | 2023-2024 | Gilotrif |
| Taiho Oncology, INC. | $106.24 | 2020-2025 | |
| Array Biopharma INC | $97.43 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Asd Specialty Healthcare, LLC | $97.30 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $93.52 | 2022 | |
| Rigel Pharmaceuticals, INC. | $84.87 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Karyopharm Therapeutics INC. | $79.34 | 2023-2024 | Xpovio |
| Servier Pharmaceuticals LLC | $69.88 | 2024-2025 | |
| Acrotech Biopharma INC. | $63.23 | 2022-2025 | Beleodaq |
| Tesaro, INC. | $60.44 | 2019 | |
| Adc Therapeutics America, INC. | $54.16 | 2024-2025 | |
| Beone Medicines USA, INC. | $51.40 | 2025 | Tevimbra, Brukinsa |
| Tg Therapeutics, INC. | $49.99 | 2021 | |
| Beigene USA, INC. | $48.36 | 2023-2025 | Brukinsa, Tevimbra |
| Apellis Pharmaceuticals, INC. | $45.55 | 2022-2024 | Empaveli |
| Mirati Therapeutics, INC. | $45.08 | 2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $43.07 | 2019-2023 | Imbruvica |
| Sun Pharmaceutical Industries INC. | $42.34 | 2022-2023 | Yonsa, Odomzo |
| Deciphera Pharmaceuticals INC. | $41.91 | 2023-2025 | Qinlock, Romvimza |
| Morphosys, US INC. | $41.18 | 2022-2023 | Monjuvi |
| Foundation Medicine, INC. | $37.92 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $35.53 | 2024 | Rybrevant |
| Tersera Therapeutics LLC | $34.86 | 2024-2025 | Zoladex |
| Kyowa Kirin, INC. | $34.58 | 2019-2025 | |
| Epizyme, INC. | $32.48 | 2021 | |
| Organon LLC | $29.92 | 2021-2023 | Ontruzant |
| Adaptive Biotechnologies Corporation | $29.60 | 2023 | Clonoseq |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Aveo Pharmaceuticals, INC. | $24.32 | 2025 | |
| Coherus Oncology, INC. | $24.27 | 2024 | |
| Geron Corporation | $23.69 | 2025 | Rytelo |
| Legend Biotech USA INC. | $21.70 | 2025 | Carvykti |
| Recordati_rare_diseases_inc. | $19.58 | 2025 | Sylvant |
| Springworks Therapeutics, INC. | $16.11 | 2024 | Ogsiveo |
| Cti Biopharma Corp. | $14.58 | 2022 | |
| Btg International INC. | $14.32 | 2019 | |
| Iovance Biotherapeutics, INC. | $14.19 | 2025 | Amtagvi |
| Dova Pharmaceuticals | $12.89 | 2020 | |
| Aurobindo Pharma USA, INC. | $12.03 | 2019 | |
| Heron Therapeutics, INC. | $12.03 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $11.43 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,663.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.